The National Institutes of Health (NIH) announced this week that its Investigational New Drug (IND) application for mitragynine has officially taken effect with the FDA, allowing researchers to begin testing the compound in humans for the first time.
For the millions of people researching treatment options for themselves or a loved one, this development signals that the addiction treatment landscape may be expanding, even though any new therapy is still years away from clinical availability.
What Is Mitragynine and Why It Matters
Mitragynine is the primary psychoactive compound found in kratom, a tropical tree native to southeast Asia. According to NIH, interest in kratom as a self-managed remedy for opioid withdrawal and pain has grown significantly in recent years.
Researchers at NIH and the University of Florida developed a purified formulation of mitragynine specifically for clinical study.
Preclinical research led by scientists at the University of Florida along with NIH’s National Center for Advancing Translational Sciences (NCATS) and National Institute on Drug Abuse (NIDA) found that mitragynine, across multiple doses, did not raise significant safety concerns in animal models.
The First Human Safety Study
With the IND now in effect, NIH scientists are preparing to launch a randomized, double-blind, placebo-controlled study, the first of its kind, to evaluate the safety and tolerability of the mitragynine formulation in people.
The trial is registered on ClinicalTrials.gov and falls under the NIH HEAL (Helping to End Addiction Long-term) Initiative, a federal effort focused on improving addiction treatment and pain management.
NIDA Director Dr. Nora Volkow framed the milestone as part of a broader push to address the country’s overdose crisis, noting it represents an important move toward expanding treatment options for people affected by opioid use disorder.
NCATS Director Dr. Joni Rutter added that years of lab research are finally translating into human study, with the hope that it leads to new treatment options that support long-term recovery.
Where Mitragynine Fits Among Treatment Options
It’s important for treatment seekers to understand that mitragynine is still in early, phase I research and is not yet an approved or available addiction treatment.
Current evidence-based options for opioid use disorder, such as buprenorphine, methadone and naltrexone, remain the standard of care and are already accessible through licensed treatment centers.
This early-stage research adds to a growing pipeline of medication options under federal study, alongside other recent NIH-backed advances such as extended-release buprenorphine formulations.
What This Means for Treatment Seekers
This trial does not change treatment access today, but it reflects continued federal investment in expanding medication options for opioid use disorder.
People currently seeking help should know that FDA-approved medications for opioid use disorder are already available at many accredited rehab centers nationwide.
Anyone considering treatment should ask facilities directly about which medications and therapies they offer, since options can vary by location and level of care.
Finding the Right Rehab
As research into new treatment options continues, choosing a rehab center remains a deeply personal decision that should factor in accreditation, levels of care and access to medications for opioid use disorder. People exploring care should consider:
- Comparing rehab centers that offer medication-assisted treatment (MAT)
- Understanding insurance coverage for addiction treatment before enrolling
- Asking facilities about evidence-based therapies, including counseling paired with FDA-approved medications
- Verifying a facility’s credentials, licensing, and clinical staff qualifications
Rehab.com’s directory includes thousands of verified rehab centers. Call
800-985-8516
( 
Sponsored Helpline )
to get started with your recovery today.
